Stryker Corporation (NYSE:SYK) – Analysts at Jefferies Group issued their Q1 2018 earnings estimates for Stryker Corporation in a report released on Thursday. Jefferies Group analyst R. Denhoy anticipates that the medical technology company will earn $1.61 per share for the quarter. Jefferies Group also issued estimates for Stryker Corporation’s Q2 2018 earnings at $1.68 EPS, Q3 2018 earnings at $1.67 EPS, Q4 2018 earnings at $2.14 EPS, FY2018 earnings at $7.09 EPS and FY2020 earnings at $8.47 EPS.
Several other analysts have also issued reports on SYK. Morgan Stanley reiterated an “overweight” rating and issued a $160.00 target price (up previously from $155.00) on shares of Stryker Corporation in a research report on Monday, July 10th. BMO Capital Markets reiterated a “hold” rating and issued a $140.00 target price on shares of Stryker Corporation in a research report on Tuesday, July 11th. Zacks Investment Research upgraded shares of Stryker Corporation from a “hold” rating to a “buy” rating and set a $163.00 target price on the stock in a research report on Monday, July 17th. Royal Bank Of Canada lifted their target price on shares of Stryker Corporation from $140.00 to $155.00 and gave the company an “outperform” rating in a research report on Friday, July 28th. Finally, Oppenheimer Holdings, Inc. set a $148.00 target price on shares of Stryker Corporation and gave the company a “hold” rating in a research report on Friday, July 28th. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and twelve have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $151.52.
Shares of Stryker Corporation (NYSE:SYK) traded down 0.22% during mid-day trading on Monday, reaching $154.53. 741,884 shares of the company’s stock traded hands. Stryker Corporation has a 12-month low of $106.48 and a 12-month high of $160.62. The company’s 50 day moving average is $146.25 and its 200 day moving average is $142.26. The company has a market cap of $57.80 billion, a P/E ratio of 34.49 and a beta of 0.80.
Stryker Corporation (NYSE:SYK) last announced its quarterly earnings results on Thursday, October 26th. The medical technology company reported $1.52 EPS for the quarter, topping the consensus estimate of $1.50 by $0.02. The business had revenue of $3.01 billion for the quarter, compared to analysts’ expectations of $2.97 billion. Stryker Corporation had a net margin of 14.67% and a return on equity of 24.11%. The business’s quarterly revenue was up 6.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.39 EPS.
Several institutional investors and hedge funds have recently made changes to their positions in SYK. Acrospire Investment Management LLC acquired a new stake in shares of Stryker Corporation during the second quarter valued at about $111,000. Bollard Group LLC increased its position in shares of Stryker Corporation by 0.4% during the second quarter. Bollard Group LLC now owns 832 shares of the medical technology company’s stock valued at $115,000 after acquiring an additional 3 shares during the last quarter. Motco increased its position in shares of Stryker Corporation by 50.7% during the second quarter. Motco now owns 826 shares of the medical technology company’s stock valued at $115,000 after acquiring an additional 278 shares during the last quarter. Bruderman Asset Management LLC acquired a new stake in shares of Stryker Corporation during the second quarter valued at about $150,000. Finally, James Investment Research Inc. acquired a new stake in shares of Stryker Corporation during the second quarter valued at about $155,000. Institutional investors and hedge funds own 74.00% of the company’s stock.
In other Stryker Corporation news, insider Lonny J. Carpenter sold 5,000 shares of Stryker Corporation stock in a transaction dated Friday, August 4th. The shares were sold at an average price of $146.36, for a total transaction of $731,800.00. Following the completion of the sale, the insider now directly owns 88,207 shares in the company, valued at $12,909,976.52. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Graham A. Mclean sold 1,124 shares of Stryker Corporation stock in a transaction dated Tuesday, August 8th. The shares were sold at an average price of $146.26, for a total transaction of $164,396.24. Following the sale, the insider now owns 8,983 shares of the company’s stock, valued at $1,313,853.58. The disclosure for this sale can be found here. 7.40% of the stock is owned by insiders.
The company also recently announced a quarterly dividend, which was paid on Tuesday, October 31st. Shareholders of record on Friday, September 29th were paid a dividend of $0.425 per share. This represents a $1.70 dividend on an annualized basis and a yield of 1.10%. The ex-dividend date was Thursday, September 28th. Stryker Corporation’s dividend payout ratio (DPR) is presently 36.32%.
Stryker Corporation Company Profile
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
What are top analysts saying about Stryker Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Stryker Corporation and related companies.